<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131167">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01964677</url>
  </required_header>
  <id_info>
    <org_study_id>12/LO/0424 CCR3772</org_study_id>
    <nct_id>NCT01964677</nct_id>
  </id_info>
  <brief_title>MR-HIFU for Bone Metastases</brief_title>
  <official_title>Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - a Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate effectiveness of the Philips Sonalleve MR-HIFU device
      for the palliation of pain in patients with bone metastases.

      Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) uses
      ultrasound to palliate pain caused by bone metastases. The main palliative mechanism of the
      method is due to local bone denervation, caused by the heat denaturation of the periosteum
      layer in the treated area. The importance of this therapy is that it offers a non-invasive,
      focal therapy, avoiding side-effects to surrounding normal tissue that occur with radiation
      therapy or the need for needle insertion as with radio-frequency(RF)ablation.

      The study hypothesis is that MR-HIFU will be effective in treating the pain associated with
      bone metastases
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain response</measure>
    <time_frame>30 days post-treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cancer</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>MR-HIFU of painful bone metastases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)</intervention_name>
    <arm_group_label>MR-HIFU of painful bone metastases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  radiologic evidence of bone metastases from any solid tumour

          -  diagnosis of dominant painful bone metastasis

          -  target lesion less than 8cm

        Exclusion Criteria:

          -  primary bone tumours rather than metastases

          -  Inability to tolerate stationary position during treatment

          -  pregnancy

          -  MRI incompatible metal implants
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nandita deSouza, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nandita deSouza, Professor</last_name>
    <phone>0208 661 3289</phone>
    <email>nandita.desouza@icr.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine May, BSc</last_name>
    <phone>0208 642 6011</phone>
    <phone_ext>4109</phone_ext>
    <email>katherine.may@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nandita deSouza, Professor</last_name>
      <phone>0208 661 3289</phone>
      <email>nandita.desouza@icr.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Katherine May, BSc</last_name>
      <phone>0208 661 3340</phone>
      <email>katherine.may@rmh.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 15, 2013</lastchanged_date>
  <firstreceived_date>October 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Cancer Research, United Kingdom</investigator_affiliation>
    <investigator_full_name>NdeSouza</investigator_full_name>
    <investigator_title>Professor of Translational Imaging</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging (MRI)</keyword>
  <keyword>High Intensity Focused Ultrasound (HIFU)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
